Your session is about to expire
← Back to Search
Photobiomodulation
Real LED Intervention for Traumatic Brain Injury
Phase < 1
Waitlist Available
Led By Paula I Martin, PhD
Research Sponsored by Boston VA Research Institute, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from 1-week to 1-month after series
Summary
This trial is exploring whether an at-home light therapy using a head frame device can help improve thinking and memory in people with mild to moderate traumatic brain injury. The therapy involves using the device for 20 minutes, 3 times a week, for 5 weeks, with a one-month break in between. There will be 4 office visits for paper and pencil testing, and 3 office visits for MRI scans. The trial will last for about 4 months.
Eligible Conditions
- Traumatic Brain Injury
- Cognitive Impairment
- Head Injuries
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ change from 1-week to 1-month after series
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from 1-week to 1-month after series
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
CVLT-II, Long Delay Free Recall 1
CVLT-II, Long Delay Free Recall 2
CVLT-II, Long Delay Free Recall 3
+1 moreSecondary study objectives
Beck Depression Inventory (BDI) 1
Beck Depression Inventory (BDI) 2
Beck Depression Inventory (BDI) 3
+85 moreTrial Design
2Treatment groups
Active Control
Placebo Group
Group I: Real LED InterventionActive Control1 Intervention
Participants receive 15 Real (active) LED treatments with the Vielight Neuro Alpha head frame device (with intranasal). Parameters: NIR, 810nm, pulsed at 10 Hz, 50% duty cycle, synchronized for a 20-minute treatment time. Total Energy Dose per head set plus intranasal: 225 J/cm2+ 15 J/cm2 = 240 J/cm2 per 20 min LED treatment. Total Energy Dose delivered (3x/Week, 5 Weeks) = 3600 J/cm2. The light from these LEDs is not visible to the eye. There is no potential for eye damage because the LEDs are not laser light. The head frame device falls within the FDA category General Wellness, low-risk devices, and no medical claims are made. It is approved for use by the VA Boston Healthcare System Safety Committee and Institutional Review Board.
Group II: Sham LED InterventionPlacebo Group2 Interventions
Participants receive a series of 15 Sham (control) LED treatments with the Vielight Neuro Alpha head frame device (with intranasal) containing Sham LEDs, synchronized for a 20-minute treatment time (3x/Week, 5 Weeks). Sham and Real devices are identical in look and feel, except no photons are emitted from the Sham devices.
Find a Location
Who is running the clinical trial?
Boston VA Research Institute, Inc.Lead Sponsor
23 Previous Clinical Trials
10,826 Total Patients Enrolled
VA Boston Healthcare SystemFED
70 Previous Clinical Trials
970,538 Total Patients Enrolled
Vielight Inc.Industry Sponsor
4 Previous Clinical Trials
619 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have experienced at least one closed-head injury or traumatic brain injury.You have been diagnosed with a neurological disease like ALS, Parkinson's, or Alzheimer's.You have a serious mental illness like schizophrenia or bipolar disorder, unless it is related to diagnosed PTSD.You have a disease that requires an organ transplant.
Research Study Groups:
This trial has the following groups:- Group 1: Real LED Intervention
- Group 2: Sham LED Intervention
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger